Previous close | 67.32 |
Open | 65.79 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 65.79 - 67.11 |
52-week range | 55.64 - 98.17 |
Volume | |
Avg. volume | 562 |
Market cap | 21.67M |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
Axsome Therapeutics Inc (NASDAQ:AXSM), a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS) disorders, has reported an insider sell according to a recent SEC filing.
In this article, we will be taking a look at the 30 countries with the lowest depression rates. If you do not want to learn about the global depression treatment market, head straight to the 5 Countries with the Lowest Depression Rates. In countries with the lowest depression rates, individuals experience lower prevalence rates of […]